Harrow (HROW) Net Income towards Common Stockholders (2010 - 2026)

Harrow's (HROW) quarterly Net Income towards Common Stockholders came in at -$27.6 million in Q1 2026, down 55.24% year-on-year from -$61.7 million in Q1 2025, and down 365.48% quarter-over-quarter from $10.4 million in Q4 2025.

Harrow (HROW) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Harrow's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$27.6 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 55.24% year-over-year to -$27.6 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 48.42% increase from a year earlier, with the FY2025 full-year figure at -$5.1 million, up 70.6% from the prior year.
  • Net Income towards Common Stockholders fell to -$27.6 million in Q1 2026 per HROW's latest filing, from $10.4 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $10.4 million in Q4 2025 and bottomed at -$27.6 million in Q1 2026.
  • The 5-year median for Net Income towards Common Stockholders is -$4.4 million (2023), against an average of -$5.0 million.
  • Across the five-year window, Net Income towards Common Stockholders plunged 1223.5% in 2022 and surged 177.17% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at $1.1 million in 2022, then plunged by 967.11% to -$9.1 million in 2023, then surged by 174.08% to $6.8 million in 2024, then surged by 53.42% to $10.4 million in 2025, then plunged by 365.48% to -$27.6 million in 2026.
  • Per Business Quant, the three latest HROW Net Income towards Common Stockholders figures stand at -$27.6 million (Q1 2026), $10.4 million (Q4 2025), and $1.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Harrow 1.41 Bn 1.32 Bn 27.05 Mn -27.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -27.60 Mn
Dec 31, 2025 10.40 Mn
Sep 30, 2025 1.02 Mn
Jun 30, 2025 5.00 Mn
Mar 31, 2025 -17.78 Mn
Dec 31, 2024 6.78 Mn
Sep 30, 2024 -4.22 Mn
Jun 30, 2024 -6.47 Mn
Mar 31, 2024 -13.57 Mn
Dec 31, 2023 -9.15 Mn
Sep 30, 2023 -4.39 Mn
Jun 30, 2023 -4.23 Mn
Mar 31, 2023 -6.64 Mn
Dec 31, 2022 1.06 Mn
Sep 30, 2022 -6.46 Mn
Jun 30, 2022 -6.24 Mn
Mar 31, 2022 -2.44 Mn
Dec 31, 2021 -7.42 Mn
Sep 30, 2021 -8.33 Mn
Jun 30, 2021 -2.95 Mn